Subjects: Hypercholesterolemia -- drug therapy and United States / Titles: Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Hypercholesterolemia -- drug therapy ✖ Subjects United States ✖ Titles Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers ✖

1. Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers

Author(s):: Doshi, Jalpa A., author
Puckett, Justin T., author
Parmacek, Michael S., author
Rader, Daniel J., author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):: Eligibility Determination
Insurance Coverage
Insurance, Health
Proprotein Convertase 9 -- antagonists & inhibitors
Serine Proteinase Inhibitors -- economics
Serine Proteinase Inhibitors -- therapeutic use
Economics, Pharmaceutical
Formularies as Topic
Hypercholesterolemia -- drug therapy
Medicaid -- economics
Medicare -- economics
Private Sector
Public Sector
Humans
Pennsylvania
United States